Proteogenomics: advances in cancer antigen research
Proteogenomics: advances in cancer antigen research
复制标题
蛋白质基因组学：癌症抗原研究进展
DOI：
10.1080/25785826.2019.1640500
复制
发表时间：
2019
影响因子：
4.4
通讯作者：
T.
中科院分区：
文献类型：
--
作者：
Kanaseki;T. Torigoe;T.
T细胞识别由HLA分子展示的抗原肽，并特异性地消除其靶细胞。识别责任抗原以及了解细胞内产生抗原的机制对癌症免疫学同样至关重要。本文介绍了蛋白质基因组学及其在癌症抗原研究中的应用。该方法全面捕获由HLA展示的免疫肽组，揭示新的抗原类别，例如突变衍生的新抗原、剪接肽和非编码区衍生的肽。这些抗原可用作治疗靶标或生物标志物。因此，蛋白基因组学是一种很有前途的癌症抗原研究方法，有助于免疫治疗的发展。
T cells recognize antigen peptides displayed by HLA molecules and specifically eliminate their target cells. Identification of responsible antigens as well as understanding the mechanism by which antigens are produced inside cells are equally crucial for cancer immunology. In this review, we introduce proteogenomics and its applications in cancer antigen research, which leverages mass spectrometry and next-generation sequencing. The approach comprehensively captures immunopeptidome displayed by HLA, revealing new classes of antigens, such as mutation-derived neoantigens, spliced peptides, and non-coding region derived peptides. These antigens may serve as therapeutic targets or biomarkers. Thus, proteogenomics is a promising approach for cancer antigen research and contributes to immunotherapy development.